4D Molecular Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Current Ratio Growth & History (FDMT)
4D Molecular Therapeutics's current ratio was 9.39 for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.39 | −5.53 | −37.05% |
| 2024 | 2024-12-31 | 14.92 | −0.73 | −4.66% |
| 2023 | 2023-12-31 | 15.65 | 1.63 | +11.65% |
| 2022 | 2022-12-31 | 14.02 | −1.67 | −10.64% |
| 2021 | 2021-12-31 | 15.69 | −1.19 | −7.08% |
| 2020 | 2020-12-31 | 16.88 | 12.83 | +316.50% |
| 2019 | 2019-12-31 | 4.05 | — | — |
4D Molecular Therapeutics quarterly current ratio
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 8.03 | −0.71 | −8.15% |
| Q1 2026 | 2026-03-31 | 9.34 | −3.02 | −24.46% |
| Q4 2025 | 2025-12-31 | 9.39 | −5.53 | −37.05% |
| Q3 2025 | 2025-09-30 | 8.42 | −8.92 | −51.44% |
| Q2 2025 | 2025-06-30 | 8.75 | −19.74 | −69.29% |
| Q1 2025 | 2025-03-31 | 12.36 | −20.29 | −62.14% |
| Q4 2024 | 2024-12-31 | 14.92 | −0.73 | −4.66% |
| Q3 2024 | 2024-09-30 | 17.33 | −0.74 | −4.08% |
| Q2 2024 | 2024-06-30 | 28.48 | 5.37 | +23.23% |
| Q1 2024 | 2024-03-31 | 32.65 | 14.29 | +77.86% |
| Q4 2023 | 2023-12-31 | 15.65 | 1.63 | +11.65% |
| Q3 2023 | 2023-09-30 | 18.07 | 0.93 | +5.44% |
| Q2 2023 | 2023-06-30 | 23.11 | 5.91 | +34.36% |
| Q1 2023 | 2023-03-31 | 18.36 | −1.74 | −8.67% |
| Q4 2022 | 2022-12-31 | 14.02 | −1.67 | −10.64% |
| Q3 2022 | 2022-09-30 | 17.14 | 2.57 | +17.61% |
| Q2 2022 | 2022-06-30 | 17.20 | −8.00 | −31.75% |
| Q1 2022 | 2022-03-31 | 20.10 | 1.09 | +5.76% |
| Q4 2021 | 2021-12-31 | 15.69 | −1.19 | −7.08% |
| Q3 2021 | 2021-09-30 | 14.57 | — | — |
| Q2 2021 | 2021-06-30 | 25.20 | — | — |
| Q1 2021 | 2021-03-31 | 19.01 | — | — |
| Q4 2020 | 2020-12-31 | 16.88 | 12.83 | +316.50% |
| Q4 2019 | 2019-12-31 | 4.05 | — | — |
4D Molecular Therapeutics current ratio trends
Over the last five fiscal years, 4D Molecular Therapeutics's current ratio decreased from 16.88 to 9.39, a change of −7.49. The latest reported quarter, Q2 2026, shows 8.03.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗